Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/44730| Title: | Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability | Authors: | Modi, Natansh D. Swain, Sandra M. BUYSE, Marc Kuderer, Nicole M. Rowland, Andrew Rockhold, Frank W. Sorich, Michael J. Hopkins, Ashley M. |
Issue Date: | 2024 | Publisher: | LIPPINCOTT WILLIAMS & WILKINS | Source: | Journal of clinical oncology, 42 (32) , p. 3773 -3777 | Abstract: | Unlocking the full potential of clinical trials through comprehensive CSR and IPD sharing can revolutionize cancer care, enhance safety evaluations, and reduce bias in systematic reviews. It is time for all stakeholders to embrace transparency and advance patient-centered outcomes. | Notes: | Hopkins, AM (corresponding author), Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, Australia. ashley.hopkins@flinders.edu.au |
Keywords: | Humans;United States;Neoplasms;Clinical Trials as Topic;United States Food and Drug Administration;Antineoplastic Agents;Drug Approval | Document URI: | http://hdl.handle.net/1942/44730 | ISSN: | 0732-183X | e-ISSN: | 1527-7755 | DOI: | 10.1200/JCO.24.00539 | ISI #: | 001348825000018 | Category: | A2 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.